scFv-F240 (Beth Israel/Harvard Medical School)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamescFv-F240 (Beth Israel/Harvard Medical School)
Drug Alias NamescFv-F240
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionTransmembrane glycoprotein gp41 inhibitors
TargetsTransmembrane glycoprotein gp41
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBeth Israel Deaconess Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeth Israel Deaconess Medical CenterHarvard Medical School
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A